- United States
- Our innovation
Our innovation
We innovate with purpose to lead where medicine is going.
Our focus areas
Our discovery, product development and supply process
With our cross-functional approach to innovation, deep expertise, and global footprint, we aim to develop therapies for patients by inventing, licensing and acquiring new molecular entities and exploring new pathways and multi-modality treatment approaches.
23-255-richard-tillyer-part-1-who-we-are-1.mp4
23-255-richard-tillyer-part-1-who-we-are-1.mp4
Research & development
We believe there are no limits to what science can do. We work to bring breakthroughs beyond medicine to help transform patients’ lives.
Our pipeline
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
Data science and digital health
Data science and digital health accelerate our R&D engine across the entire value-chain – from target discovery and patient segmentation to drug design, CMC process optimization and all facets of clinical development.
Latest news
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Featured data include new results from the Phase 3 MARIPOSA study, which has received U.S. FDA Priority Review, and the Phase 1b PALOMA study of subcutaneous amivantamab
U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
FDA ODAC unanimously votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI® based on results from the Phase 3 CARTITUDE-4 study
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
Submission is supported by data from the Phase 3 QUASAR program, which showed a significantly greater percentage of patients with moderately to severely active ulcerative colitis who received TREMFYA® achieved clinical remission at Week 44 compared with placebo
Contact us
Our R&D leadership team is made up of passionate individuals who are helping to transform the future of healthcare.